Articles
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases…
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases…
The oral DPP-IV inhibitors vildagliptin (LAF237), sitaglitpin (MK-0431) and saxagliptin (BMS-477118) from Novartis, Merck & Co., and BMS are in advanced phase III development and compete to be “First in Class” of a new oral treatment modality for type 2 diabetes.
At least five phase II and six phase I DPP-IV inhibitors are closely following and more than 10 further companies are in advanced preclinical R&D. Available data show differences in duration of action and anticipated dosing frequency, whereas data to compare clinical efficacy and safety presently is not available. The high interest of the pharmaceutical industry reflects the market attractivity. The WHO estimates that globally over 170 mln people have diabetes, with type 2 diabetes accounting for 90 % to 95 %. By 2030, the prev…
At least five phase II and six phase I DPP-IV inhibitors are closely following and more than 10 further companies are in advanced preclinical R&D. Available data show differences in duration of action and anticipated dosing frequency, whereas data to compare clinical efficacy and safety presently is not available. The high interest of the pharmaceutical industry reflects the market attractivity. The WHO estimates that globally over 170 mln people have diabetes, with type 2 diabetes accounting for 90 % to 95 %. By 2030, the prev…
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs…
A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs…
In developing generic pharmaceuticals for today’s market there are many pitfalls, the most significant of which is infringement of patents. Based on the significant costs involved with litigation or the lost revenues from being forced to withdraw a product from the market, patent infringement is a potential threat not only to individual products, but also to any organisation without significant financial resources.
In developing generic pharmaceuticals for today’s market there are many pitfalls, the most significant of which is infringement of patents. Based on the significant costs involved with litigation or the lost revenues from being forced to withdraw a product from the market, patent infringement is a potential threat not only to individual products, but also to any organisat…
In developing generic pharmaceuticals for today’s market there are many pitfalls, the most significant of which is infringement of patents. Based on the significant costs involved with litigation or the lost revenues from being forced to withdraw a product from the market, patent infringement is a potential threat not only to individual products, but also to any organisat…
There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
By: Brian S. Robinson i3, Vice-President, Global Marketing www.i3global.com There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful. Speed is not a capabili…
By: Brian S. Robinson i3, Vice-President, Global Marketing www.i3global.com There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful. Speed is not a capabili…
27-Aug-2010
Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking greater career management/development and rapid progression.
Bill McHale and Iain Jessup – i3 Pharma Resourcing Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking gr…
Bill McHale and Iain Jessup – i3 Pharma Resourcing Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking gr…
27-Aug-2010
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes. But what is the reality, and where is the border between the promise of providers and the expectation of end users? This article is not designed to provide d…
Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes. But what is the reality, and where is the border between the promise of providers and the expectation of end users? This article is not designed to provide d…
27-Aug-2010
Free Job Postings for UK Charity Organisations in the Healthcare Sector.
If you are a UK registered charity in the healthcare sector, we can offer you FREE job postings. So, you can access 160,000 visitors per month for nothing! If you want to know more contact Mike Wood
If you are a UK registered charity in the healthcare sector, we can offer you FREE job postings. So, you can access 160,000 visitors per month for nothing! If you want to know more contact Mike Wood
27-Aug-2010
New Blog for Jobs
As part of our continuing development and improvement, we have added created a Blog of our Top Jobs. This will be updated weekly and will also include any other news or information we think is relevant relevant to Pharmaceutical job searching. Check it out here: http://pharmaceuticaljobs.blogspot.com/
As part of our continuing development and improvement, we have added created a Blog of our Top Jobs. This will be updated weekly and will also include any other news or information we think is relevant relevant to Pharmaceutical job searching. Check it out here: http://pharmaceuticaljobs.blogspot.com/
27-Aug-2010
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics.
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics. Until now, the last requirement for avian influenza viruses to cause a pandemic – efficient transmission between humans – has fortunately not been met. However, the devastating effect of the A(H5N1) bird flu on poultry holdings, and he…
Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics. Until now, the last requirement for avian influenza viruses to cause a pandemic – efficient transmission between humans – has fortunately not been met. However, the devastating effect of the A(H5N1) bird flu on poultry holdings, and he…
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration. Iron was removed from the blood and tissues of patients just as safely and effectively with the novel once-daily oral chelator treatment deferasirox (Exjade) as with the standard older injectable iron chelator deferoxamine. Th…
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration. Iron was removed from the blood and tissues of patients just as safely and effectively with the novel once-daily oral chelator treatment deferasirox (Exjade) as with the standard older injectable iron chelator deferoxamine. Th…
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years.
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years. Around 95 pe…
Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years. Around 95 pe…
27-Aug-2010
It is easy to take a surf on the internet and look at the priorities stated in NHS policy and strategy documents. However, does this really reflect the true picture on the ground? What are the big issues for NHS customers at the moment?
It is easy to take a surf on the internet and look at the priorities stated in NHS policy and strategy documents. However, does this really reflect the true picture on the ground? What are the big issues for NHS customers at the moment? We raised this question with over 70 customers during the last three months. They were from a variety of roles in primary and secondary care. Here are the top priorities, in order of importance to the customer, and some of the key comments and insights they gave. Practice Based Commissioning: Practice based commissionin…
It is easy to take a surf on the internet and look at the priorities stated in NHS policy and strategy documents. However, does this really reflect the true picture on the ground? What are the big issues for NHS customers at the moment? We raised this question with over 70 customers during the last three months. They were from a variety of roles in primary and secondary care. Here are the top priorities, in order of importance to the customer, and some of the key comments and insights they gave. Practice Based Commissioning: Practice based commissionin…
27-Aug-2010
Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer, were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
New Biologics revolutionizing treatment of colorectal cancer The market for colorectal cancer therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options. The late-stage pipeline for colorectal cancer therapies is curr…
New Biologics revolutionizing treatment of colorectal cancer The market for colorectal cancer therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options. The late-stage pipeline for colorectal cancer therapies is curr…
27-Aug-2010
Moving on inexorably carries with it the promise of ‘the farewell speech’...
There comes a time when we all have to move on, whether it be flying the parental coop to head off into the big wide world, breaking up with a lover or under threat of arrest outside the headquarters of the BBC after protesting at the recommissioning of popular ‘sitcom’, ‘Two Pints of Lager and a Packet of Crisps.’ And moving on inexorably carries with it the promise of ‘the farewell speech’. Like an ugly mate in a nightclub the farewell speech hangs around putting you off making the most of your potential but there’s no need for things to be that way, the farewell speech can not only pass off without incident, it can actually endear you to your ex-colleagues and make your superiors regret losing such a valuable em…
There comes a time when we all have to move on, whether it be flying the parental coop to head off into the big wide world, breaking up with a lover or under threat of arrest outside the headquarters of the BBC after protesting at the recommissioning of popular ‘sitcom’, ‘Two Pints of Lager and a Packet of Crisps.’ And moving on inexorably carries with it the promise of ‘the farewell speech’. Like an ugly mate in a nightclub the farewell speech hangs around putting you off making the most of your potential but there’s no need for things to be that way, the farewell speech can not only pass off without incident, it can actually endear you to your ex-colleagues and make your superiors regret losing such a valuable em…
27-Aug-2010
Clinical Research Academy (CRAcademy) has continued to find top candidates for Clinical Research Associate (CRA) posts by running a series of Selection and Assessment Days in the UK. The success of the first event led to a second in November 2005 where clients from the Pharmaceutical and Clinical Research industry joined the panel at interview.
Clinical Research Academy (CRAcademy) has continued to find top candidates for Clinical Research Associate (CRA) posts by running a series of Selection and Assessment Days in the UK. The success of the first event led to a second in November 2005 where clients from the Pharmaceutical and Clinical Research industry joined the panel at interview. The 23 candidates were chosen from over 70 applicants who expressed a desire to become Clinical Research As…
Clinical Research Academy (CRAcademy) has continued to find top candidates for Clinical Research Associate (CRA) posts by running a series of Selection and Assessment Days in the UK. The success of the first event led to a second in November 2005 where clients from the Pharmaceutical and Clinical Research industry joined the panel at interview. The 23 candidates were chosen from over 70 applicants who expressed a desire to become Clinical Research As…
27-Aug-2010
The end of year appraisal is something that many people dread, some people think that it is a complete waste of time and while others actually look forward to it. Which one of the previous descriptions fits you the best?
The end of year appraisal is something that many people dread, some people think that it is a complete waste of time and while others actually look forward to it. Which one of the previous descriptions fits you the best? If you and your manager have been having regular contact during 2005 then your end of year appraisal should have no surprises in it. It is a time that you can sparkle if you have put enough effort into your work over the proceeding year. The appraisal interview should be quality time that you have with your manager when you can revisit your successes and ac…
The end of year appraisal is something that many people dread, some people think that it is a complete waste of time and while others actually look forward to it. Which one of the previous descriptions fits you the best? If you and your manager have been having regular contact during 2005 then your end of year appraisal should have no surprises in it. It is a time that you can sparkle if you have put enough effort into your work over the proceeding year. The appraisal interview should be quality time that you have with your manager when you can revisit your successes and ac…
27-Aug-2010
Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career.
Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career. Understanding about personality tests can be a big help should you have to face one and the best way to understand them is to do one. (You try one here for free. http://www.peoplemaps.com )Your personality test results will reveal a range of things about you to a potential employer. Typically it will reveal your strengths, weaknesses and your preferred style of working and communicating. To begin with you will usually be asked to complete a Forced Choice Questionnaire if it is a sophisticated system…
Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career. Understanding about personality tests can be a big help should you have to face one and the best way to understand them is to do one. (You try one here for free. http://www.peoplemaps.com )Your personality test results will reveal a range of things about you to a potential employer. Typically it will reveal your strengths, weaknesses and your preferred style of working and communicating. To begin with you will usually be asked to complete a Forced Choice Questionnaire if it is a sophisticated system…
Treatment of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) presents unique problems. While treatments for both leukemias have advanced significantly in recent years, Datamonitor research shows that drug resistance to the gold standard treatment for CML is emerging, while current immunotherapeutic treatment for CLL is hampered by prognostic difficulties.
An estimated 300,000 new cases of leukemia are diagnosed worldwide each year, with over 220,000 deaths attributable to the disease. While each type of leukemia has its own distinctive epidemiological profile, incidence rates are generally higher for males than females and increase with age for all subtypes except acute lymphoblastic leukemia (ALL). Fighting resistance The treatment of CML was transformed with the…
An estimated 300,000 new cases of leukemia are diagnosed worldwide each year, with over 220,000 deaths attributable to the disease. While each type of leukemia has its own distinctive epidemiological profile, incidence rates are generally higher for males than females and increase with age for all subtypes except acute lymphoblastic leukemia (ALL). Fighting resistance The treatment of CML was transformed with the…
Abbott Diabetes Care today introduced the new Precision Xtra™ Plus (Optium™ Plus in some markets) Glucose Test Strip in Europe for use with the Precision™ Xceed (Optium Xceed™ in some markets) Advanced Diabetes Management System at the 41st Annual Meeting of the European Association for the Study of Diabetes in Athens, Greece. The new test strip offers results in just five seconds and requires a small blood sample of only 0.6 micro litre. The new Precision Xtra Plus test strip provides reliabl
Athens, Greece, September 13, 2005 — Abbott Diabetes Care today introduced the new Precision Xtra™ Plus (Optium™ Plus in some markets) Glucose Test Strip in Europe for use with the Precision™ Xceed (Optium Xceed™ in some markets) Advanced Diabetes Management System at the 41st Annual Meeting of the…
Athens, Greece, September 13, 2005 — Abbott Diabetes Care today introduced the new Precision Xtra™ Plus (Optium™ Plus in some markets) Glucose Test Strip in Europe for use with the Precision™ Xceed (Optium Xceed™ in some markets) Advanced Diabetes Management System at the 41st Annual Meeting of the…
